Use of cardiovascular and antidiabetic drugs before and after starting with clozapine versus other antipsychotic drugs: a Dutch database study.
Aged
Antipsychotic Agents
/ administration & dosage
Cardiovascular Agents
/ therapeutic use
Cardiovascular Diseases
/ drug therapy
Clozapine
/ administration & dosage
Diabetes Mellitus
/ drug therapy
Drug Administration Schedule
Drug Monitoring
Female
Health Status
Humans
Hypoglycemic Agents
/ therapeutic use
Insurance Claim Review
Male
Middle Aged
Netherlands
/ epidemiology
Schizophrenia
/ drug therapy
Journal
International clinical psychopharmacology
ISSN: 1473-5857
Titre abrégé: Int Clin Psychopharmacol
Pays: England
ID NLM: 8609061
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
pubmed:
13
11
2019
medline:
9
6
2020
entrez:
13
11
2019
Statut:
ppublish
Résumé
Reports of decreased mortality among patients with schizophrenia who use clozapine may be biased if clozapine is prescribed to relatively healthy patients and if intensive monitoring during its use prevents (under-treatment of) somatic disorder. We aimed to assess whether there is a difference in: (1) somatic comorbidity between patients who start with clozapine and those who start with other antipsychotics and (2) prescribed somatic medication, between patients using clozapine and those using olanzapine. Cohort study based on insurance claims (2010-2015). After selecting new users of antipsychotics and those who subsequently switched to clozapine (N = 158), aripiprazole (N = 295), olanzapine (N = 204) or first-generation antipsychotics (N = 295), we compared the clozapine starters to others on cardiovascular or diabetic comorbidity. Those using clozapine and olanzapine were compared on new prescriptions for cardiovascular or antidiabetic drugs. The ORadj of cardiovascular or diabetic comorbidity among other starters compared with clozapine starters was 0.77 [95% confidence interval (CI): 0.43-1.39], that is, a nonsignificantly increased prevalence associated with clozapine was found. Users of clozapine received significantly more new prescriptions for cardiovascular or antidiabetic medication (ORadj: 2.70, 95% CI: 1.43-5.08). Starters with clozapine were not cardiovascular/metabolic healthier than starters with other antipsychotics. During its use, they received more somatic treatment.
Identifiants
pubmed: 31714320
doi: 10.1097/YIC.0000000000000292
pii: 00004850-202001000-00005
doi:
Substances chimiques
Antipsychotic Agents
0
Cardiovascular Agents
0
Hypoglycemic Agents
0
Clozapine
J60AR2IKIC
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
36-41Références
Birkenaes AB, Birkeland KI, Engh JA, Faerden A, Jonsdottir H, Ringen PA, et al. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol. 2008; 28:132–137
De Berardis D, Rapini G, Olivieri L, Di Nicola D, Tomasetti C, Valchera A, et al. Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. Ther Adv Drug Saf. 2018; 9:237–256
de Silva VA, Suraweera C, Ratnatunga SS, Dayabandara M, Wanniarachchi N, Hanwella R. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry. 2016; 16:341
Hayes RD, Downs J, Chang CK, Jackson RG, Shetty H, Broadbent M, et al. The effect of clozapine on premature mortality: an assessment of clinical monitoring and other potential confounders. Schizophr Bull. 2015; 41:644–655
Hirsch L, Yang J, Bresee L, Jette N, Patten S, Pringsheim T. Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies. Drug Saf. 2017; 40:771–781
Jesus C, Jesus I, Agius M. What evidence is there to show which antipsychotics are more diabetogenic than others? Psychiatr Danub. 2015; 27Suppl 1S423–S428
Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988; 45:789–796
Kelly AC, Sheitman BB, Hamer RM, Rhyne DC, Reed RM, Graham KA, et al. A naturalistic comparison of the long-term metabolic adverse effects of clozapine versus other antipsychotics for patients with psychotic illnesses. J Clin Psychopharmacol. 2014; 34:441–445
Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev(3). 2010Cd006654
Kugathasan P, Horsdal HT, Aagaard J, Jensen SE, Laursen TM, Nielsen RE. Association of secondary preventive cardiovascular treatment after myocardial infarction with mortality among patients with schizophrenia. JAMA Psychiatry. 2018; 75:1234–1240
Laursen TM, Munk-Olsen T, Gasse C. Chronic somatic comorbidity and excess mortality due to natural causes in persons with schizophrenia or bipolar affective disorder. Plos One. 2011; 6:e24597
Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol. 2014; 10:425–448
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013; 382:951–962
Miller DD. Review and management of clozapine side effects. J Clin Psychiatry. 2000; 61Suppl 814–17; discussion 18
Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016; 209:385–392
Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017; 13:757–777
Souza JS, Kayo M, Tassell I, Martins CB, Elkis H. Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses. CNS Spectr. 2013; 18:82–89
Swildens W, Termorshuizen F, de Ridder A, Smeets H, Engelhard IM. Somatic care with a psychotic disorder. Lower somatic health care utilization of patients with a psychotic disorder compared to other patient groups and to controls without a psychiatric diagnosis. Adm Policy Ment Health. 2016; 43:650–662
Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009; 374:620–627
van der Zalm YC, Termorshuizen F, Schulte PF, Bogers JP, Marcelis M, Sommer IE, Selten JP. Prescription and underprescription of clozapine in dutch ambulatory care. Front Psychiatry. 2018; 9:231
van der Zalm YC, Termorshuizen F, Selten JP. Concerns about bias in studies on clozapine and mortality. Schizophr Res. 2019; 204:425–426
Vanasse A, Blais L, Courteau J, Cohen AA, Roberge P, Larouche A, et al. Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real-world observational study. Acta Psychiatr Scand. 2016; 134:374–384
Vermeulen JM, van Rooijen G, van de Kerkhof MPJ, Sutterland AL, Correll CU, de Haan L. Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1-12.5 years. Schizophr Bull. 2019; 45:315–329
Wimberley T, MacCabe JH, Laursen TM, Sørensen HJ, Astrup A, Horsdal HT, et al. Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia. Am J Psychiatry. 2017; 174:990–998